Table 1.

Clinicopathological correlation of ACSL4 expression in human HCC.

Variables	Tumor ACSL4 expression
	Low	High	p-valuea
Age
≤50 years	19 (47.5%)	21 (52.5%)	0.354
>50 years	27 (57.4%)	20 (42.6%)
Gender
Female	5 (62.5%)	3 (37.5%)	0.567
Male	41 (51.9%)	38 (48.1%)
HBsAg status
Negative	9 (52.9%)	8 (47.1%)	0.995
Positive	37 (52.9%)	33 (47.1%)
Cirrhosis
Absent	5 (55.6%)	4 (44.4%)	0.865
Present	41 (52.6%)	37 (47.4%)
Tumor encapsulation
Complete	20 (50%)	20 (50%)	0.620
No complete	26 (55.3%)	21 (44.7%)
Tumor size
≤5 cm	29 (47.5%)	32 (52.5%)	0.127
>5 cm	17 (65.4%)	9 (34.6%)
Tumor number
Single	43 (55.8%)	34 (44.2%)	0.123
Multiple	3 (30%)	7 (70%)
Edmondson–Steiner grade
I–II	35 (54.7%)	26 (45.3%)	0.572
III–IV	11 (47.8%)	12 (52.2%)
PVTT
Absent	32 (50.8%)	31 (49.2%)	0.529
Present	14 (58.3%)	10 (41.7%)
Alpha-fetoprotein level
≤20 ng/ml	25 (71.4%)	10 (28.6%)	0.030
>400 ng/ml	14 (45.2%)	17 (54.8%)

^ap-values were derived with a two-tailed Pearson chi-square test.